Juvenile Arthritis

 

Children Face Added Risks With Corticosteroid Use

October 22, 2020

Children who take oral corticosteroids for autoimmune conditions, such as juvenile arthritis, psoriasis, inflammatory bowel disease or other conditions, like asthma, have an increased risk of diabetes, high blood pressure, and blood clots, say researchers writing in the American Journal of Epidemiology.

Genomic Risk Scores May Enhance JIA Diagnosis

October 05, 2020

In juvenile idiopathic arthritis, predictive genomic risk scores may enhance current diagnosis protocols, prioritizing higher-risk patients for follow-up and reducing treatment delays, according to a study published this month in Annals of Rheumatic Diseases.

Tofacitinib Approved for Juvenile Arthritis

September 30, 2020

The U.S. Food and Drug Administration has approved tofacitinib Xeljanz, Pfizer) for the treatment of children and adolescents two years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA).

Tocilizumab May Help Uveitis in Juvenile Idiopathic Arthritis

March 03, 2020

Tocilizumab might be a useful adjunctive therapeutic option for children with juvenile idiopathic arthritis-associated uveitis that doesn't respond to TNFi treatment, say researchers recently writing in The Lancet Rheumatology.

Psoriasis Risk Rises with TNF Inhibitor Use in Pediatric Inflammatory Diseases

November 27, 2019

Children with inflammatory bowel disease, juvenile idiopathic arthritis, and chronic noninfectious osteomyelitis who were treated with TNF inhibitors had a higher rate of incident psoriasis than those not exposed to these biologics, say researchers recently writing in Arthritis Care & Research.

JIA Disease Activity Persists, Despite Lower Uveitis, Major Joint Surgery Rates

November 27, 2019

While the need for orthopedic surgery and the presence of uveitis have diminished over the past 20 years in children with juvenile idiopathic arthritis (JIA), disease activity is present more than 50 percent of the time, say researchers recently writing in Arthritis Research and Therapy.

One Step Closer for Macrophage Activation Syndrome Testing in Juvenile Arthritis

November 18, 2019

Researchers reporting at the annual meeting of the American College of Rheumatology earlier this month say they have successfully identified a specific biomarker for macrophage activation syndrome, a complication of childhood rheumatic disease most often affecting children with systemic juvenile idiopathic arthritis.

ACR Annual Meeting Roundup: Higher death rates in lupus

November 14, 2019

In today's slideshow, we highlight the best of the ACR Annual Meeting which wrapped this week in Atlanta. Among the highlights, includes a study that focuses on unusually high death rates in lupus, plus one that suggests new treatments for juvenile idiopathic arthritis are "urgently" needed. Learn more in this slideshow.